维拉帕米联合化疗药物治疗恶性胸腹水的临床观察  

Clinical effect of verapamil combined with chemotherapeutics in perfusion treating hydrothorax and seroperitoneum

作　　者：刘亚贝[1] 李烨[1] 唐艳[1] 陈曼萍[2] 胡冰[2] 林新民[2] 鲁朝晖[1] 范平生[1] 

机构地区：[1]安徽省肿瘤医院肿瘤内科,安徽合肥230031 [2]安徽省立医院肿瘤内科,安徽合肥230001

出　　处：《安徽医药》2010年第4期453-455,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察胸/腹腔灌注维拉帕米及化疗药物的疗效和毒副作用。方法57例恶性胸/腹腔积液,胸腹腔联合灌注维拉帕米及化疗药物,1个周期治疗后评价疗效及毒副反应。结果胸/腹腔灌注的有效率(CR+PR)为89.5%,其中胸水的总有效率(CR+PR)为88.9%,腹水的总有效率(CR+PR)为90.0%。Ⅰ度胃肠道反应(42.1%),2例II度消化道反应,灌注部位轻度疼痛(22.8%),发热(19.3%),白细胞下降(10.5%)。结论维拉帕米联合化疗药物胸/腹腔灌注可以提高胸腹水治疗的有效率。Aim To observe the therapeutic effect of therapeutic alliance of verapamil and chemotherapeutics splanchnocoel perfusion. Methods 57 hydrothorax and seroperitoneum were splanchonocoel perfused with verapamil and chemotherapeutics,therapeutic effect evaluated after 2 courses of treatment. Results The general effective rate of splanchnocoel perfusion was 89.5% , including hydrothorax 88.9% and seropelitoneum 90.0%. The incidence of untoward reaction were nausea and vomiting 42.1% , mild pain 22.8% ,fever 19. 3% ,leucocyte decrease 10.5%. Conclusion Therapeutic alliance of verapamil and chemotherapeutics splanchnocoel perfusion could increase therapeutic effective rate of hydrothorax and seoperitoneum.

关 键 词：胸/腹水 维拉帕米 P-糖蛋白 多药耐药 灌注化疗 

分 类 号：R730.5[医药卫生—肿瘤]